Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant hexavalent norovirus vaccine
- Development stage
- Unknown
- Lead developer
- Chengdu Kanghua Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
**Recombinant hexavalent norovirus vaccine** is an investigational, Pichia pastoris-expressed virus-like particle vaccine developed by Chengdu Kanghua Biological Products for prevention of norovirus infection and norovirus-associated acute gastroenteritis. The product contains virus-like-particle antigens representing norovirus genotypes GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17. It is administered as an injection and is in randomized, double-blind, placebo-controlled Phase 1 evaluation in healthy participants aged 6 weeks and older in China. ([static.cninfo.com.cn](https://static.cninfo.com.cn/finalpage/2026-01-26/1224950746.PDF))
- Other names
- recombinant hexavalent norovirus vaccine Pichia pastoris重组六价诺如病毒疫苗重组六价诺如病毒疫苗毕赤酵母
02
Targets
BCR-NV-VP1 (B-cell receptor (BCR) specific for norovirus VP1 conformational epitopes)Norovirus VP1TCR-VP1-MHCII (T-cell receptor recognizing VP1-derived peptides presented on MHC class II)
Beyond the preview
Go deeper on recombinant hexavalent norovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant hexavalent norovirus vaccine.